The potential of protein kinase C as A target for anticancer treatment

Research output: Contribution to journalReview article

199 Citations (Scopus)

Abstract

Many investigators have embarked upon the search for novel cellular targets for the treatment of cancer. A popular therapeutic strategy is to intervene with the components of cellular signalling systems that are altered during malignancy. The molecular heterogeneity of the protein kinase C (PKC) family and their functional divergence make them attractive targets for anticancer drug development. PKC can also influence the sensitivity of tumor tissue to conventional cytotoxic drugs. As discussed in this review, a complete understanding of the PKC signal transduction pathway is obligatory for the selective destruction of tumor tissue by exploiting PKC as either a target or a modulator of cancer chemotherapeutic agents.

Original languageEnglish
Pages (from-to)257-280
Number of pages24
JournalPharmacology and Therapeutics
Volume59
Issue number3
DOIs
StatePublished - 1 Jan 1993

Fingerprint

Protein Kinase C
Neoplasms
Pharmaceutical Preparations
Signal Transduction
Research Personnel
Therapeutics

Cite this

@article{8c08390f7029472fa2d3c03b06c8680a,
title = "The potential of protein kinase C as A target for anticancer treatment",
abstract = "Many investigators have embarked upon the search for novel cellular targets for the treatment of cancer. A popular therapeutic strategy is to intervene with the components of cellular signalling systems that are altered during malignancy. The molecular heterogeneity of the protein kinase C (PKC) family and their functional divergence make them attractive targets for anticancer drug development. PKC can also influence the sensitivity of tumor tissue to conventional cytotoxic drugs. As discussed in this review, a complete understanding of the PKC signal transduction pathway is obligatory for the selective destruction of tumor tissue by exploiting PKC as either a target or a modulator of cancer chemotherapeutic agents.",
author = "Alakananda Basu",
year = "1993",
month = "1",
day = "1",
doi = "10.1016/0163-7258(93)90070-T",
language = "English",
volume = "59",
pages = "257--280",
journal = "Pharmacology and Therapeutics",
issn = "0163-7258",
publisher = "Elsevier Inc.",
number = "3",

}

The potential of protein kinase C as A target for anticancer treatment. / Basu, Alakananda.

In: Pharmacology and Therapeutics, Vol. 59, No. 3, 01.01.1993, p. 257-280.

Research output: Contribution to journalReview article

TY - JOUR

T1 - The potential of protein kinase C as A target for anticancer treatment

AU - Basu, Alakananda

PY - 1993/1/1

Y1 - 1993/1/1

N2 - Many investigators have embarked upon the search for novel cellular targets for the treatment of cancer. A popular therapeutic strategy is to intervene with the components of cellular signalling systems that are altered during malignancy. The molecular heterogeneity of the protein kinase C (PKC) family and their functional divergence make them attractive targets for anticancer drug development. PKC can also influence the sensitivity of tumor tissue to conventional cytotoxic drugs. As discussed in this review, a complete understanding of the PKC signal transduction pathway is obligatory for the selective destruction of tumor tissue by exploiting PKC as either a target or a modulator of cancer chemotherapeutic agents.

AB - Many investigators have embarked upon the search for novel cellular targets for the treatment of cancer. A popular therapeutic strategy is to intervene with the components of cellular signalling systems that are altered during malignancy. The molecular heterogeneity of the protein kinase C (PKC) family and their functional divergence make them attractive targets for anticancer drug development. PKC can also influence the sensitivity of tumor tissue to conventional cytotoxic drugs. As discussed in this review, a complete understanding of the PKC signal transduction pathway is obligatory for the selective destruction of tumor tissue by exploiting PKC as either a target or a modulator of cancer chemotherapeutic agents.

UR - http://www.scopus.com/inward/record.url?scp=0027435064&partnerID=8YFLogxK

U2 - 10.1016/0163-7258(93)90070-T

DO - 10.1016/0163-7258(93)90070-T

M3 - Review article

C2 - 8309991

AN - SCOPUS:0027435064

VL - 59

SP - 257

EP - 280

JO - Pharmacology and Therapeutics

JF - Pharmacology and Therapeutics

SN - 0163-7258

IS - 3

ER -